Phase 2 Study of NGM282 in Patients With Primary Biliary Cirrhosis

Summary

The purpose of this study is to determine the safety, tolerability, and activity of NGM282 in patients with Primary Biliary Cirrhosis.

Timeline

Start

2014-02

Primary completion

2014-12

Completion

2014-12

Outcome

Met primary endpoint

release “Data from the trial demonstrated a statistically significant and clinically meaningful percentage reduction in ALP from baseline to day 28 in both NGM282 treatment arms” ngmbio.com ↗

Drugs

Indications